Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species
- PMID: 7838170
- DOI: 10.1016/0166-6851(94)90100-7
Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species
Abstract
Antibodies raised against a Leishmania major recombinant promastigote surface antigen 2 (PSA-2) fragment recognized three major polypeptides of approximate M(r) 96,000, 80,000 and 50,000 in promastigotes of three Israeli isolates of L. major including the cloned line LRC-L137-V121, but detected a different array of polypeptides in other L. major isolates. The pattern was different both in number of polypeptides detected and their molecular weight. The antibodies to L. major PSA-2 also recognized polypeptides in L. tropica, L. donovani and very weakly in L. mexicana promastigotes and in Crithidia lucilliae. The number and size of the polypeptides was different in each species. In addition to the membrane-bound PSA-2 polypeptides we identified water-soluble forms of PSA-2 released in promastigote culture supernatants. Peptide maps of the various L. major PSA-2 membrane polypeptides showed they were different from each other. N-terminal amino acid sequence of the three polypeptides expressed by L. major showed they are similar but distinct, consistent with being members of a polymorphic family. Because of the extensive sequence similarity between the PSA-2 genes it has been difficult to assign protein products to individual genes. As a first step towards solving this problem, we have transfected into L. mexicana a genomic clone of a L. major PSA-2 gene and shown that it produces a M(r) 35,000 polypeptide recognized by monoclonal and polyclonal antibodies to L. major PSA-2.
Similar articles
-
The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle.Mol Biochem Parasitol. 1995 Nov;74(2):189-200. doi: 10.1016/0166-6851(95)02500-6. Mol Biochem Parasitol. 1995. PMID: 8719160
-
Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.Infect Genet Evol. 2014 Jun;24:1-14. doi: 10.1016/j.meegid.2014.02.017. Epub 2014 Mar 7. Infect Genet Evol. 2014. PMID: 24614507
-
The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen.J Immunol. 1989 Dec 15;143(12):4221-6. J Immunol. 1989. PMID: 2592773
-
Evolution and expression of the Leishmania surface proteinase (gp63) gene locus.Infect Agents Dis. 1993 Feb;2(1):25-34. Infect Agents Dis. 1993. PMID: 8162351 Review.
-
Molecular variation in Leishmania.Acta Trop. 1993 May;53(3-4):185-204. doi: 10.1016/0001-706x(93)90029-b. Acta Trop. 1993. PMID: 8100670 Review.
Cited by
-
Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.PLoS Negl Trop Dis. 2016 May 25;10(5):e0004614. doi: 10.1371/journal.pntd.0004614. eCollection 2016 May. PLoS Negl Trop Dis. 2016. PMID: 27223609 Free PMC article.
-
Leishmania mexicana mutants lacking glycosylphosphatidylinositol (GPI):protein transamidase provide insights into the biosynthesis and functions of GPI-anchored proteins.Mol Biol Cell. 2000 Apr;11(4):1183-95. doi: 10.1091/mbc.11.4.1183. Mol Biol Cell. 2000. PMID: 10749923 Free PMC article.
-
Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.Infect Immun. 1995 Nov;63(11):4261-7. doi: 10.1128/iai.63.11.4261-4267.1995. Infect Immun. 1995. PMID: 7591056 Free PMC article.
-
In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.PLoS One. 2014 May 2;9(5):e92708. doi: 10.1371/journal.pone.0092708. eCollection 2014. PLoS One. 2014. PMID: 24786587 Free PMC article.
-
Immunoinformatic Analysis of Leishmania Major gp46 Protein and Potential Targets for Vaccination against Leishmaniasis.Recent Adv Inflamm Allergy Drug Discov. 2024;18(2):129-139. doi: 10.2174/0127722708283588240124095057. Recent Adv Inflamm Allergy Drug Discov. 2024. PMID: 38318831
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous